logo Hematology/Oncology Research Studies: Open for Enrollment Date: 02/12/19


Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35), or Crizotinib (commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma

NCT#/Phase: NCT01979536
Phase 2
IRB#: 2014-021
Description: This is a Phase 2 study to determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (ALCL99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99). On this study, patients with newly diagnosed ALCL will be randomized to receive standard chemotherapy plus brentuximab vedotin (Arm BV) or standard chemotherapy plus crizotinib (Arm CZ).
Inclusion: Individuals must be < 22 years of age at the time of study enrollment and be newly diagnosed with histologically proven ALCL. In addition, the disease must be CD30 positive, ALK positive, and either Stage II, III, or IV.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group
Principal Investigator(s): Carla Golden, MD
Contact(s): Christine Ho (510-428-3885 x 2609)
Diane Olzewski (510-428-3885 x 3246)
Study Link: https://www.clinicaltrials.gov/ct2/show/NCT01979536

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000